Evidence map›Paper›PMID 40511650›Full record

ArticleCurrent medical imaging2025

Application Value of Enhanced CT Imaging Features in Predicting Vessels Encapsulating Tumor Clusters (VETC) Positivity in Hepatocellular Carcinoma.

Qianjiang Ding, Xi Deng, Jingfeng Huang, Ruixue Zhang, Ting Liu, Jianhua Wang, Yutao Wang

Abstract read
In one paragraph

Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qianjiang DingDepartment of Radiology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China.
Xi DengDepartment of Pathology, Ningbo Clinical Pathology Diagnosis Center, Ningbo, Zhejiang 315021, China.
Jingfeng HuangDepartment of Radiology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China.
Ruixue ZhangDepartment of Ultrasound, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China.
Ting LiuDepartment of Radiology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China.
Jianhua WangDepartment of Radiology, The First Affiliated Hospital of Xiamen University,Xiamen, Fujian 361000,China.
Yutao WangDepartment of Radiology, Ningbo Ninth Hospital, Ningbo, Zhejiang 315020, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVETC-positive has emerged as a novel predictor of HCC for poor prognosis. Enhanced CT is one of the most common diagnostic methods, which can indicate VETC positivity, providing important evidence for the diagnosis and treatment of VETC-positive HCC.

objectiveThe objective of this study is to investigate the clinical and preoperative enhanced CT imaging characteristics and diagnostic value of VETCpositive hepatocellular carcinoma (HCC) patients.

methodsA retrospective analysis was conducted on the clinical, pathological, and imaging data of 53 HCC patients from the First Affiliated Hospital of Ningbo University between June 2019 and September 2022. According to pathological results, patients were categorized into 11 VETC-positive and 42 VETC-negative cases. Observational parameters included: (1) Clinical indicators: gender, age, history of hepatitis B virus infection, preoperative AFP, TNM staging, and preoperative biochemical and coagulation laboratory tests, including Alb, AST, ALT, TBil, DB, PT, TT, and INR. Additionally, pathological results such as histological grading, microvascular invasion (MVI), satellite nodules, neural invasion, and postoperative recurrence were analyzed. (2) Preoperative enhanced CT observational indicators: maximum tumor diameter, intrahepatic growth, irregular tumor margins, peritumoral hepatic parenchymal enhancement, mosaic structure, non-ring-like arterial phase hyperenhancement, marked heterogeneous enhancement, non-peripheral washout, absence of enhancing capsule, enhancing/clear capsule, intratumoral arteries, intratumoral necrosis, along with measurement of unenhanced CT values and enhanced CT values at various phases, calculating enhancement ratios (enhancement ratio = enhanced CT value - unenhanced CT value / unenhanced CT value). Quantitative data were expressed as mean ± standard deviation (x̅±s), with intergroup comparisons conducted using the t-test; categorical variables were compared using the χ

results(1) Clinical characteristics of VETC-positive versus VETC-negative patients: Preoperative AFP levels showed statistical significance (P=0.037), while no significant differences were observed in gender, age, Alb, TB, DB, AST, ALT, PT, TT, and INR between VETC-positive and VETCnegative patients (P>0.05). (2) Enhanced CT imaging features of VETC-positive versus VETC-negative patients: Intratumoral necrosis showed statistical significance (P<0.05), with intratumoral arteries being 63.6% (7/11) in the positive group compared to 42.9% (18/42) in the negative group. No significant differences were found in maximum tumor diameter, irregular tumor margins, peritumoral hepatic parenchymal enhancement, mosaic structure, non-ring-like arterial phase hyperenhancement, marked heterogeneous enhancement, non-peripheral washout, absence of enhancing capsule, enhancing capsule, intratumoral arteries, as well as unenhanced CT values and enhanced CT values at various phases, arterial phase enhancement ratio, portal phase enhancement ratio, and delayed phase enhancement ratio (P>0.05). (3) Multivariate analysis influencing VETC positivity: Arterial phase CT values (HU) (OR=0.937, P=0.029), intratumoral arteries (OR=9.452, P=0.021), and intratumoral necrosis (OR=0.013, P=0.003) were identified as independent risk factors for VETC positivity (Odds Ratio=0.937, 9.452, 0.013, 95% CI=0.883-0.993, 1.4-63.823, 0.001-0.223, P<0.05). The AUC of VETC was 0.863 (95% CI: 0.728-0.997), with a sensitivity of 81.8% and specificity of 88.1%. (4) Postoperative early tumor recurrence in VETC-positive and VETC-negative patients: All 53 patients were followed up, with an average tumor recurrence time of 11 (4-20) months, showing significant differences (P<0.05).

conclusionAs one of the routine and preferred methods for HCC examination, enhanced CT plays a pivotal role in diagnosis, staging, and post-treatment evaluation. Combining preoperative enhanced arterial phase CT values, intratumoral arteries, and intratumoral necrosis can highly indicate VETC positivity.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNeovascularization, PathologicTomography, X-Ray ComputedAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesComputed Tomography(CT)Enhanced CT.HeparHepatocellular carcinomaVessels Encapsulating Tumor Clusters (VETC)VETC-positive

Identifiers

PMID40511650
PMCPMC13223500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.